SCHEMBL7703786

SCHEMBL7703786

O=C1c2cccc3cc([N+](=O)[O-])cc(c23)C(=O)N1O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.67
KMT2A Q03164 6/20 0.67
NTRK1 P04629 1/20 0.65
NGFR P08138 1/20 0.65
FTO Q9C0B1 2/20 0.62
PABPC1 P11940 2/20 0.62
POLB P06746 5/20 0.61
TDP1 Q9NUW8 1/20 0.61
MAPT P10636 3/20 0.60
CA12 O43570 3/20 0.60
CA1 P00915 3/20 0.60
CA2 P00918 3/20 0.60
CA9 Q16790 3/20 0.60
KDM4E B2RXH2 2/20 0.60
RAB9A P51151 2/20 0.60
S1PR1 P21453 1/20 0.60
HTT P42858 1/20 0.60
RAD52 P43351 1/20 0.60
RECQL P46063 1/20 0.60
PAX8 Q06710 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7709452 0.88 MEN1 (0.58) MEN1KMT2ANTRK1NGFRFTO
SCHEMBL28125149 0.87 MEN1 (0.64) MEN1KMT2ANTRK1NGFRFTO
SCHEMBL12237994 0.85 FTO (0.69) MEN1KMT2ANTRK1NGFRFTO
SCHEMBL1901643 0.82 FTO (0.72) MEN1KMT2ANTRK1NGFRFTO
SCHEMBL11438964 0.82 FTO (0.68) MEN1KMT2ANTRK1NGFRFTO
SCHEMBL717142 0.82 CA12 (0.74) MEN1KMT2ANTRK1NGFRFTO
SCHEMBL9550381 0.82 NTRK1 (0.61) MEN1KMT2ANTRK1NGFRFTO
SCHEMBL13495360 0.82 FTO (0.61) MEN1KMT2ANTRK1NGFRFTO
SCHEMBL5116172 0.81 MEN1 (0.66) MEN1KMT2ANTRK1NGFRFTO
SCHEMBL14159191 0.81 CA12 (0.73) MEN1KMT2ANTRK1NGFRFTO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6362181-B1 BACTERICIDES; ENZYME INHIBITORS; ANTITUMOR AGENTS WARNER-LAMBERT COMPANY 2002-03-26 US claimed
EP-0939754-A2 N-OXY-NAPHTHALIMIDES AS ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY (US) 1999-09-08 EP claimed
WO-1998019648-A2 N-OXY-NAPHTHALIMIDES AS ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY (US) 1998-05-14 WO claimed
US-20230128889-A1 REL/RELA/SPOT SMALL MOLECULES MODULATORS AND SCREENING METHODS Université Libre de Bruxelles (BE) 2023-04-27 US disclosed
US-20230128889-A1 REL/RELA/SPOT SMALL MOLECULES MODULATORS AND SCREENING METHODS Université Libre de Bruxelles (BE) 2023-04-27 US disclosed
CN-110041202-B Preparation method of 1, 8-disubstituted naphthalene mononitration derivative 长江大学 2022-04-19 CN disclosed
CN-110041203-A A kind of 1,8- bis- replaces the preparation method of naphthalene system condensed-nuclei aromatics mono-nitration derivative 长江大学 2019-07-23 CN disclosed
CN-110041202-A A kind of 1,8- bis- replaces the preparation method of naphthalene mono-nitration derivative 长江大学 2019-07-23 CN disclosed
WO-2014179528-A2 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS BROWN DENNIS M (US) 2014-11-06 WO disclosed
WO-2013059582-A2 SMALL MOLECULE INHIBITORS OF HISTONE DEACTEYLASES NUPOTENTIAL, INC. (US) 2013-04-25 WO disclosed
US-20110262383-A1 Naphthalimide Dosing by N-Acetyl Transferase Genotyping CHEMGENEX PHARMACEUTICALS, INC. (US) 2011-10-27 US disclosed
EP-2305257-A1 Amonafide salts and compositions comprising same ChemGenex Pharmaceuticals, Inc. (US) 2011-04-06 EP disclosed
US-20110003742-A1 Naphthalimide Dosing by N-Acetyl Transferase Genotyping CHEMGENEX PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-6362181-B1 BACTERICIDES; ENZYME INHIBITORS; ANTITUMOR AGENTS WARNER-LAMBERT COMPANY 2002-03-26 US disclosed
US-6177423-B1 N-(HYDROXY OR PROTECTED HYDROXY)-BENZO(DE)ISOQUINOLINE-1,3-DIONE DERIVATIVES; BACTERIAL DNA GYRASE AND DNA TOPOISOMERASE INHIBITORS USEFUL FOR ANTIBACTERIAL AGENTS HAVING REDUCED DRUG RESISTANCE AND REDUCED SIDE EFFECTS WARNER-LAMBERT COMPANY 2001-01-23 US disclosed
EP-0939754-A2 N-OXY-NAPHTHALIMIDES AS ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY (US) 1999-09-08 EP disclosed
WO-1998019648-A2 N-OXY-NAPHTHALIMIDES AS ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY (US) 1998-05-14 WO disclosed
US-5237059-A Compounds capable of generating an acid by light irradiation FUJI PHOTO FILM CO., LTD. (JP) 1993-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110262383-A1 Naphthalimide Dosing by N-Acetyl Transferase Genotyping NAT1, NCF1, GGCT MEN1 3298/4885KMT2A 1648/4885NTRK1 1473/4885
US-20110003742-A1 Naphthalimide Dosing by N-Acetyl Transferase Genotyping NAT1, NCF1, GGCT MEN1 3298/4885KMT2A 1648/4885NTRK1 1473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.